Thursday, March 16, 2017 4:30:03 PM
'Pursuant to the Collaboration Agreement, we are responsible for completing the three ENCORE trials and the POLT-HCV-SVR trial described above . Prior to Novartis’ exercise of the option, Novartis will reimburse us for any costs of the se four Phase 2 b t rials that exceed an agreed upon budget or we will credit any amount under budget to Novartis’ future costs for the four Phase 2 b t rials. If Novartis exercises its option, we will share the costs of the se four Phase 2 b trials equally with Novartis after the effective date of the license grant under the Collaboration Agreem ent . Novartis will also be responsible for 100% of certain expenses for required registration-supportive nonclinical activities . Novartis will be responsible for the development of emricasan beyond the four Phase 2 b trials described above , including the Ph ase 3 development of emricasan single agent products and all development for emricasan combination products , and Novartis has agreed to use commercially reasonable efforts to develop and commercialize emricasan products , if the option is exercised . A joint steering committee comprised of representatives from our company and Novartis will oversee the collaboration, development and commercialization of emricasan products.'
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM